Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019
Autor: | Antonio Riccardo Buonomo, Isabella Di Filippo, Nunzia Esposito, Gabriele Saccone, Mariano Nobile, Giulio Viceconte, Riccardo Villari, Costantino Di Carlo, Giuseppe Bifulco, Ivan Gentile |
---|---|
Rok vydání: | 2023 |
Předmět: | |
Zdroj: | American Journal of Perinatology. |
ISSN: | 1098-8785 0735-1631 |
Popis: | Objective The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study Design We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab. Results Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease. Conclusion Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease. Key Points |
Databáze: | OpenAIRE |
Externí odkaz: |